Zhejiang Yatai Pharmaceutical Co., Ltd.

This product has a broad-spectrum antibacterial effect, especially high antibacterial activity against aerobic Gram-negative rods, and has good antibacterial activity against the following bacteria in vitro: 1. Most bacteria of the Enterobacteriaceae family, including Citrobacter, Enterobacter cloacae, Enterobacter aerogenes, Escherichia coli, Klebsiella, Proteus, Salmonella, Shigella, Vibrio, Yersinia, etc. It also has high antibacterial activity against penicillin-resistant Neisseria gonorrhoeae, enzyme-producing Haemophilus influenzae, and Moraxella. 2. It has antibacterial activity against most strains of Pseudomonas, such as Pseudomonas aeruginosa. 3. It has antibacterial activity against methicillin-sensitive Staphylococcus aureus, and only moderate antibacterial activity against Streptococcus pneumoniae, hemolytic Streptococcus, and Enterococcus faecalis. It has good antimicrobial effects against Chlamydia trachomatis, Mycoplasma, and Legionella, and also has antibacterial activity against Mycobacterium tuberculosis and atypical mycobacteria. It has poor antibacterial activity against anaerobic bacteria. 4. Ofloxacin is a bactericide that acts on the A subunit of bacterial DNA helicase, inhibiting DNA synthesis and replication, leading to bacterial death. The drug resistance of this product is currently increasing, and there is cross-resistance with other quinolones.

This product belongs to the third generation of cephalosporin, with a broad-spectrum antibacterial effect, and is stable against broad-spectrum β-lactamases (including penicillinase and cephalosporinase) produced by various Gram-positive and Gram-negative bacteria. It has a strong antibacterial effect on Enterobacteriaceae such as Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis. Pseudomonas and Acinetobacter species such as Pseudomonas aeruginosa are less sensitive to this product. It has a good antibacterial effect on Haemophilus influenzae and Neisseria gonorrhoeae. The effect on Staphylococcus aureus and Staphylococcus epidermidis is worse than that of the first and second generation cephalosporins. Methicillin-resistant Staphylococcus aureus and Enterococcus are resistant to this product, and various streptococci are highly sensitive to this product. Anaerobic bacteria such as Peptococcus, Peptostreptococcus and some Bacteroides are mostly sensitive to this product, and Clostridium difficile is sensitive to this product.

This product belongs to the third generation of cephalosporin, with a broad-spectrum antibacterial effect, and is stable to β-lactamase produced by most bacteria. This product is mainly effective against a variety of G+ and G- bacteria and anaerobic bacteria. It has an immunomodulatory effect, that is, it can be used as a biological response modifier (BRM) to increase CD4 in the body, thereby increasing the CD4/CD8 value and playing a synergistic bactericidal effect. This product is ineffective against Bacteroides, Acinetobacter, Enterococcus faecalis, Listeria, Mycoplasma, and Chlamydia. The mechanism of action of this product is that this product achieves a bactericidal effect by inhibiting the biosynthesis of bacterial cell wall mucopeptides.

Amoxicillin is a broad-spectrum penicillin antibiotic, which can protect it from beta-lactamase hydrolysis when used in combination with potassium clavulanate. It has a good effect on enzyme-producing Staphylococcus aureus, Staphylococcus epidermidis, coagulase-negative Staphylococci and enterococci, and also has good antibacterial activity against certain beta-lactamase-producing Enterobacteriaceae, Haemophilus influenzae, Moraxella catarrhalis, Bacteroides fragilis, etc.

Potassium clavulanate itself has only weak antibacterial activity, but it has a strong broad-spectrum beta-lactamase inhibitory effect and can protect amoxicillin from beta-lactamase hydrolysis.

This product is a semi-synthetic 14-membered macrolide antibiotic. Its antibacterial spectrum and antibacterial effect are basically similar to those of erythromycin. Its effect on Gram-positive bacteria is slightly worse than that of erythromycin, and its effect on Legionella pneumophila is stronger than that of erythromycin. Its antimicrobial effect on Chlamydia pneumoniae, Mycoplasma pneumoniae, and Ureaplasma urealyticum is similar to or slightly stronger than that of erythromycin. This product can penetrate the bacterial cell membrane and reversibly bind to the 50S subunit of the bacterial ribosome near the donor (P position), blocking the transfer RNA (t-RNA) from binding to the P position, and also blocking the transfer of the polypeptide chain from the acceptor position (A position) to the P position, thereby inhibiting bacterial protein synthesis.